{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:14Z","timestamp":1792788314854,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Medical College of Wisconsin Department of Surgery","id":[{"id":"https:\/\/ror.org\/00qqv6244","id-type":"ROR","asserted-by":"crossref"}]},{"name":"WeCare Fund for Medical Innovation and Research"},{"name":"Ronald Burkland Eich Pancreatic Cancer Research Fund","id":[{"id":"https:\/\/ror.org\/04ef2za66","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Advancing a Healthier Wisconsin Fund","award":["5520161"],"award-info":[{"award-number":["5520161"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.surg.2020.04.031","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T16:08:20Z","timestamp":1593965300000},"page":"440-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer"],"prefix":"10.1016","volume":"168","author":[{"given":"Chad A.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen K.","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callisia N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulwinder","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-2712","authenticated-orcid":false,"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2020.04.031_bib1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gassur.2005.09.016","article-title":"Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings","volume":"10","author":"Hishinuma","year":"2006","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2020.04.031_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"and the European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2020.04.031_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jamcollsurg.2015.12.031","article-title":"Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?","volume":"222","author":"Parikh","year":"2016","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib6","doi-asserted-by":"crossref","first-page":"36903","DOI":"10.18632\/oncotarget.5054","article-title":"Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns","volume":"6","author":"Wangjam","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.surg.2020.04.031_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11605-008-0762-x","article-title":"Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio","volume":"13","author":"Asiyanbola","year":"2009","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib9","doi-asserted-by":"crossref","first-page":"dju011","DOI":"10.1093\/jnci\/dju011","article-title":"Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy","volume":"106","author":"Sohal","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.surg.2020.04.031_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamasurg.2016.1113","article-title":"Therapeutic advances in localized pancreatic cancer","volume":"151","author":"Tsai","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1245\/s10434-009-0413-9","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement","volume":"16","author":"Abrams","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.surg.2020.04.031_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.surg.2015.09.018","article-title":"Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy","volume":"159","author":"Christians","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2020.04.031_bib14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","article-title":"Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma","volume":"269","author":"Groot","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib15","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"and the Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2020.04.031_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2014.09.010","article-title":"Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer","volume":"113","author":"Kharofa","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11605-016-3265-1","article-title":"Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A 25-year single-institution experience","volume":"21","author":"Cloyd","year":"2017","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib18","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1245\/s10434-015-4649-2","article-title":"Non-metastatic pancreatic cancer: Resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy","volume":"22","author":"Evans","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib19","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1245\/s10434-019-07738-5","article-title":"Goals of treatment sequencing for localized pancreatic cancer","volume":"26","author":"Evans","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.suc.2009.12.001","article-title":"Portal vein resection","volume":"90","author":"Christians","year":"2010","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.surg.2020.04.031_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jso.23166","article-title":"Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma","volume":"107","author":"Christians","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.pan.2014.09.006","article-title":"Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis","volume":"14","author":"Yamamoto","year":"2014","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2020.04.031_bib23","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2005.05.3934","article-title":"Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma","volume":"24","author":"Ferrone","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s11605-007-0243-7","article-title":"Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer","volume":"11","author":"House","year":"2007","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"Suppl 3","key":"10.1016\/j.surg.2020.04.031_bib25","doi-asserted-by":"crossref","first-page":"S1187","DOI":"10.1245\/s10434-015-4861-0","article-title":"Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: Proposal for a revised n classification for tnm staging","volume":"22","author":"Basturk","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s11605-017-3544-5","article-title":"Is adjuvant therapy necessary for all patients with localized pancreatic cancer who have received neoadjuvant therapy?","volume":"21","author":"Barnes","year":"2017","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/his.12732","article-title":"The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy","volume":"68","author":"Fischer","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.surg.2020.04.031_bib28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.gassur.2006.08.018","article-title":"1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience","volume":"10","author":"Winter","year":"2006","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib30","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1245\/s10434-014-3842-z","article-title":"Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma","volume":"21","author":"Boone","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","article-title":"Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation","volume":"17","author":"Katz","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.031_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archsurg.2012.1126","article-title":"Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma","volume":"147","author":"Gnerlich","year":"2012","journal-title":"Arch Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib33","first-page":"1756","article-title":"Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion","volume":"61","author":"Suenaga","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.surg.2020.04.031_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11605-007-0384-8","article-title":"Pancreatic adenocarcinoma: the actual 5-year survivors","volume":"12","author":"Ferrone","year":"2008","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"3 Suppl 1","key":"10.1016\/j.surg.2020.04.031_bib35","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.surg.2012.05.020","article-title":"Pancreatic ductal adenocarcinoma: long-term survival does not equal cure","volume":"152","author":"Ferrone","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2020.04.031_bib36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/SLA.0000000000002557","article-title":"and the European Study Group for Pancreatic Cancer. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma","volume":"269","author":"Ghaneh","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hpb.12058","article-title":"Impact of preoperative therapy on patterns of recurrence in pancreatic cancer","volume":"16","author":"Papavasiliou","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2020.04.031_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.surg.2020.04.031_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jamcollsurg.2011.09.022","article-title":"Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy","volume":"214","author":"Mayo","year":"2012","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.surg.2020.04.031_bib41","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer [epub ahead of print]","author":"Truty","year":"2019","journal-title":"Ann Surg"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020302403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020302403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:54:35Z","timestamp":1758538475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606020302403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0039606020302403"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2020.04.031","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2020.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}